We present the validation of an improved gene-specific sequencing assay for the detection of variants across the coding regions of SMN1 and SMN2. Given advancements in SMA therapeutics, expanding molecular diagnostic testing for symptomatic individuals with a single SMN1 allele is imperative for detecting therapy-eligible patients. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.